Table 2 Clinical trials of ASI in advanced CRC

[27]

Anti-Id 3H1

i.c

AH

23

0

0

NR

[28]

CEA/HbsAg-CMV

i.m

HBsAg

17

0

0

0

[29]

DC-CEA peptid

i.v

No

10

1

1

2

[30]

ALVAC(CEA-B7.1)

i.m

ALVAC/B7.1

13

0

0

2

[31]

DC-CEA peptid

i.v

No

7

0

0

1

[32]

Auto-tumor

i.d

NDV

13

4

0

8

[33]

DC-CEA peptid

i.t

No

10

0

0

2

[34]

Virus CEA

s.c

GM-CSF\IL-2

11

0

0

NI

[35]

Virus CEA

i.d/s.c

Tricom/GM-CSF

35

0

0

14

[36]

DC-CEA peptid

s.c

No

7

0

0

2

[37]

SART3 peptide

s.c

IFA

12

0

0

1

[38]

DC-CEA transfected

i.v+id

IL-2

11

0

0

0

[39]

DC-CEA peptid

s.c+id

Tricom

11

0

0

6

[40]

DC + tumor RNA

i.v

KLH

15

0

0

0

[41]

DC+MAGE3 peptide

i.v

No

3

0

1

0

[42]

SART-IcK-CyB multi peptide

s.c

Montanideisa-51

10

0

1

1

[43]

Survive peptide

s.c

No

17

0

1

3

[44]

DC + CEA peptide

s.c/i.d

No

11

0

0

3

[45]

ALVAC expressing CEA+B7.1

i.d

B7.1

28

0

0

7

[46]

Autologous hemoderivative

s.c

GM-CSF

50

0

0

26

[47]

DC+allogeneic tumor cell lysate

i.d

No

17

0

0

4

[48]

TroVax

i.m

MVA

17

0

0

5

[49]

P53-SLP

s.c

No

10

0

0

4

[50]

tumor lysate pulsed-Dc

i.t

THI

8

0

0

4

[51]

Aex+GM-CSF

s.c

GM-CSF

20

0

1

1

[52]

DC+MHC-I peptide

i.d

IFN-[r]/GM-CSF

11

0

0

0

[53]

Glutaraldehyde-fixed HUVECs

i.d

No

3

0

0

0

[54]

Xenogenic polyantigenic vaccine

s.c

IL-2

37

2

10

11

[55]

Oncolytic poxvirus JX-594

PEIT

GM-CSF

4

0

0

3

[56]

MIDGE

s.c

d-SLIM

10

2

1

2

[57]

ALVAC-p53

i.v

ALVAC

16

0

0

1

[58]

ONYX-015 adevirus

i.v

No

18

0

0

7

[59]

TNFa AutoVaccIne

i.m

AH

33

2

0

7

[60]

rF-CEA-TRICOM

i.d

B7.1

11

0

1

4

[61]

CEA alt-plused DC

iv

No

7

0

0

1

[62]

DC-CEA peptid

i.t

IL-4/GM-CSF

10

0

0

2

[63]

Murine monoclonal CEA-antibody

i.d

AH

15

0

0

1

[64]

Ep-CAM protein

s.c

MPL/GM-CSF

11

0

0

3

[65]

Vaccine virus expressing CEA

i.d/s.c

No

20

0

0

2

[66]

DC + CEA peptide

i.v/i.d

IL-2

11

0

0

0

[67]

Antibody SCV 106 mimicking 17-1A

s.c

AH

21

0

0

0

[68]

Autologous tumor

s.c

Fibroblasts/IL-2

10

0

0

1

[69]

retroviral vector- IL-2 allogeneic tumor cells + IL-1a

i.d

DETOX/IL-1a

22

0

2

0

Total

43

656

11(1.68%)

19(2.9%)

141(21.49%)